Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Third Quarter 2021 Financial Results
SOLANA BEACH, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate
View HTML
Toggle Summary Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021
SOLANA BEACH, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its third quarter 2021 financial results on
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
Health care practitioners’   perception of nasal route of administration similar to IV;  92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas , October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO , Oct.
View HTML
Toggle Summary Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI
Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments
View HTML
Toggle Summary Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SOLANA BEACH, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R .Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2021 Financial Results
Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
View HTML
Toggle Summary Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021
SOLANA BEACH, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its second quarter 2021 financial results
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders’ (IFFGD) August Gastroparesis Awareness Month
Participating and Sponsorship in Upcoming Digestive Health Virtual Walk SOLANA BEACH, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma ® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA ™ , a leading provider of global
View HTML
Toggle Summary Evoke Pharma Launches Gimoti® Patient and Physician Experience Program
Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers SOLANA BEACH, Calif. , July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced
View HTML
Toggle Summary Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council
Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk SOLANA BEACH, Calif. , CHICAGO , and MOUNT PLEASANT, S.C. , June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML